¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"competitive protein binding radioassay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • principal outer membrane protein
    ÁÖ¹Ù±ù¸·´Ü¹éÁú, Áֿܸ·´Ü¹éÁú
  • prosthetic protein
    ¹èÇմܹéÁú
  • protein
    ´Ü¹éÁú
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
  • protein granule
    ´Ü¹éÁú°ú¸³
  • protein kinase
    ´Ü¹éÁúŰ³ª¾ÆÁ¦
  • protein kinase C
    ´Ü¹éÁúŰ³ª¾ÆÁ¦C
  • protein layer
    ´Ü¹éÁúÃþ
  • protein p53
    ´Ü¹éÁúp53
  • protein quotient
    ´Ü¹éÁúÁö¼ö
  • protein S
    ´Ü¹éÁúS
  • protein score
    ´Ü¹éÁú°¡
  • protein sensitization
    ´Ü¹éÁú¹Î°¨È­
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹é, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • protein
    ´Ü¹é, ´Ü¹éÁú
  • principal outer membrane protein
    Áֿܸ·´Ü¹éÁú
  • prosthetic protein
    ¹èÇմܹé
  • protein quotient
    ´Ü¹éÁö¼ö
  • protein score
    ´Ü¹é°¡
  • protein sensitization
    ´Ü¹é¹Î°¨
  • reserve protein
    ÀúÀå´Ü¹éÁú
  • specific protein
    ƯÀ̴ܹéÁú
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
  • stress protein
    ½ºÆ®·¹½º´Ü¹éÁú
  • structural protein
    ±¸Á¶´Ü¹é, ±¸Á¶´Ü¹éÁú
  • vehicle protein
    ¿î¹Ý´Ü¹éÁú
  • stable plasma protein solution
    ¾ÈÁ¤Ç÷Àå´Ü¹é¿ë¾×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • heterologous protein
    ÀÌÁ¾´Ü¹é.
  • high protein diet
    °í´Ü¹é½Ä(ÀÌ)(ÍÔÓ±ÛÜãÝìÈ).
  • immune protein
    ¸é¿ª´Ü¹éÁú.
  • inner membrane protein
    ³»¸·´Ü¹éÁú
  • insoluble protein
    ºÒ¿ë¼º ´Ü¹é(Áú).
  • perturbation of protein
    ´Ü¹éÁúº¯ÅÂ(Ó±ÛÜòõ ܨ÷¾).
  • pilus protein antigen
    ¼¶¸ð´Ü¹éÁúÇ׿ø
  • plasma protein
    Ç÷Àå´Ü¹éÁú(úìíìÓ±ÛÜòõ).
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
  • plasma protein fraction =PCC
    Ç÷Àå´Ü¹éºÐȹ
  • principal outer membrane protein (POMP)
    ÁÖ¿ä¿Ü¸·´Ü¹éÁú
  • prosthetic protein
    ¹èÇÕ¼º ´Ü¹é(ÛÕùêàõÓ±ÛÜ).
  • protein
    ´Ü¹éÁú
  • protein
    ´Ü¹é(Ó±ÛÜ), ´Ü¹éÁú(Ó±ÛÜòõ)
  • protein
    ´Ü¹é(Áú)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • iron-binding capacity
    ö°áÇÕ´É
  • orthodontic binding wire =o. ligature wire
    ±³Á¤¿ë °áÂû¼±(ÎìïáéÄÌ¿óÏàÊ).
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇÕ±Û·Îºí¸°
  • sex-hormone binding globulin
  • testosterone-binding globulin
    Å×½ºÅ佺Å×·Ð °áÇմܹé
  • thyroid-binding globulin
  • thyroxin binding globulin
    Ƽ·Ï½Å°áÇձ۷κҸ°.
  • thyroxin binding prealbumin
    Ƽ·Ï½Å°áÇÕÇÁ¸®¾ËºÎ¹Î.
  • thyroxine -binding globulin
    Ƽ·Ï½Å°áÇÕ±Û·Îºí¸°
  • thyroxine-binding prealbumin
    Ƽ·Ï½Å°áÇÕÇÁ¸®¾ËºÎ¹Î
  • total iron binding capacity
    ÃÑö°áÇÕ´É
  • total iron binding capacity=TIBC
    ÃÑö°áÇÕ´É
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É(¡­ôÑÌ¿ùêÒö).
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • aldosterone-induced protein
    ¾Ëµµ½ºÅ×·ÐÀ¯µµ ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
  • A myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ) A
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anion-transport protein
    À½À̿¿î¹Ý(ê¡Úõ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • antifreeze protein
    Ç×°áºù´Ü¹éÁú(ù÷̿޼ӱÛÜòõ)
  • antitumor protein
    Ç×Á¾¾ç ´Ü¹éÁú(ù÷ðþåËÓ±ÛÜòõ)
  • antiviral protein
    Ç×(ù÷) ¹ÙÀÌ·¯½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • A protein
    A ´Ü¹éÁú(Ó±ÛÜòõ)
  • azo-dye protein
    ¾ÆÁ¶»ö¼Ò ´Ü¹éÁú(ßäáÈÓ±ÛÜòõ)
  • Bence-Jones protein
    º¥½º-Á¸½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • biotin carboxyl carrier protein
    ¹ÙÀÌ¿Àƾ Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • blue copper protein
    ûµ¿ ´Ü¹éÁú(ôìÔÞÓ±ÛÜòõ)
  • blue protein
    û´Ü¹éÁú(ôìÓ±ÛÜòõ)
  • B protein
    B ´Ü¹éÁú(Ó±ÛÜòõ)
  • Ca2+-dependent regulatory protein
    Ca2+-ÀÇÁ¸(ëîðí) Á¶Àý´Ü¹éÁú(ðàï½Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CMO cardiac minute output; Chief Medical Officer; comfort measures only; competitive medical organizatio...
VOO ventricular asynchronous (competitive, fixed-rate) [pacemaker]
CBG capillary blood gases; coronary bypass graft; corticosteroid-binding globulin; cortisol-binding glob...
IBC Institutional Biosafety Committee; iodine-binding capacity; iron-binding capacity; isobutyl cyanoacr...
TBA tertiary butylacetate; testosterone-binding affinity; tetrabutylammonium; thiobarbituric acid; to be...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ABP Actin Binding Protein
ACBP Acyl-CoA binding protein
ALBP Adipocyte lipid binding protein
ABP Androgen Binding Protein
ABP1 Auxin-binding protein
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
insulin-like growth-factor-binding proteins A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9)
(12 Dec 1998)
iron-binding capacity The capacity of iron-binding protein in serum (transferrin) to bind serum iron.
(05 Mar 2000)
testosterone-oestrogen-binding globulin A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma.
(12 Dec 1998)
thyroid binding globulin <protein> Thyroid binding globulin (TBG) is a plasma protein which binds the majority of thyroid hormone in the bloodstream. Bound thyroid hormone is inactive, only the unbound fraction (0.3%) is considered active. Birth control pills and pregnancy can lead to increased TBG levels in the plasma. Androgens can decrease TBG levels in the plasma.
(27 Sep 1997)
thyroxine-binding globulin An alpha-globulin of blood with a strong binding affinity for thyroxine; triiodothyronine is bound to it much less firmly; a deficiency or excess of this protein may occur as a rare benign X-linked disorder.
Synonym: thyroxine-binding protein.
(05 Mar 2000)
thyroxine-binding proteins A group of proteins that includes thyroxine-binding globulin, a glycoprotein that serves as the major and specific carrier of thyroxine in plasma, accounting for 70-75% of the bound thyroxine; thyroxine-binding prealbumin, an albumin that serves as the secondary carrier, accounting for between 20 and 25% of the bound thyroxine; and serum albumin, which accounts for the remaining bound thyroxine.
(12 Dec 1998)
total iron binding capacity <biochemistry, haematology> A test that measures indirectly the transferrin level in the bloodstream.
Transferrin is a protein that carries iron in the body. Normal values are 240 to 450 mcg/dl. This test is used to evaluate anaemia. Greater than normal total iron binding capacity can be seen in: iron deficiency anaemia, late pregnancy and polycythaemia vera.
Lower than normal total iron binding capacity can be seen in cirrhosis, sickle cell anaemia, hypoproteinaemia, pernicious anaemia and haemolytic anaemia. The use of birth control pills can lead to increased total iron binding capacity measurements.
Acronym: TIBC
(12 Jan 1998)
fatty acid binding proteins <biochemistry> Group of small cytosolic proteins that bind fatty acids or other organic solutes.
(18 Nov 1997)
zero time-binding DNA DNA that has become the duplex form at the start of a reassociation process.
Acronym: DNA
(05 Mar 2000)
ligand binding site The site on a protein's surface that binds a ligand; equivalent to the active site if the ligand is the substrate of an enzyme.
(05 Mar 2000)
acetoacetyl-acyl carrier protein synthase <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin
Registry number: EC 2.3.1.-
Synonym: acetoacetyl-acp synthase
(26 Jun 1999)
acid soluble spore protein <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light.
(18 Nov 1997)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acyl-(acyl-carrier-protein)-phospholipid acyltransferase <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine
Registry number: EC 2.3.1.40
Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase
(26 Jun 1999)
acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source
Registry number: EC 2.3.1.129
Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á